Haleon (LON:HLN) Shares Cross Below Two Hundred Day Moving Average – What’s Next?

Haleon plc (LON:HLN)’s share price crossed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of GBX 360.62 and traded as low as GBX 310.50. Haleon shares last traded at GBX 316.60, with a volume of 1,048,323,188 shares.

More Haleon News

Here are the key news stories impacting Haleon this week:

• Positive Sentiment: Haleon launched a £500 million share buyback, which should support earnings per share, return capital to investors and help fund employee share plans. Management also maintained its profit guidance. Haleon launches £500 million share buyback programme
• Neutral Sentiment: Third-quarter organic revenue increased 2.6%, while Haleon’s consumer-health portfolio continued to grow overall. However, the result was below management’s expectations, making the buyback appear more defensive than growth-driven. Haleon Q3 2026 trading update
• Negative Sentiment: Haleon reduced its fiscal 2026 organic revenue-growth forecast to approximately 2.5%, from a previous range of 3% to 5%. The downgrade reinforces investor concerns that sales momentum is slowing. Haleon trims 2026 growth outlook
• Negative Sentiment: Weaker-than-expected cough, cold and flu consumption reduced North American orders, while a raw-material classification change disrupted OTC-registered Centrum products in China. Haleon also expects a fourth-quarter revenue impact from accelerating a go-to-market change in Brazil. Haleon cuts revenue growth forecast

Analyst Ratings Changes

HLN has been the topic of a number of recent research reports. Deutsche Bank Aktiengesellschaft dropped their target price on Haleon from GBX 335 to GBX 320 and set a “sell” rating on the stock in a report on Wednesday, September 9th. Jefferies Financial Group reiterated a “buy” rating and set a GBX 400 price target on shares of Haleon in a report on Friday, July 31st. Royal Bank Of Canada increased their price target on Haleon from GBX 370 to GBX 390 and gave the company a “sector perform” rating in a research report on Tuesday, August 11th. Finally, Berenberg Bank raised their price objective on Haleon from GBX 512 to GBX 514 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of GBX 387.80.

Haleon Price Performance

The business has a 50 day moving average price of GBX 353.77 and a two-hundred day moving average price of GBX 360.62. The stock has a market cap of £28.51 billion, a PE ratio of 17.91, a P/E/G ratio of 1.49 and a beta of 0.24. The company has a debt-to-equity ratio of 50.38, a quick ratio of 0.93 and a current ratio of 0.69.

Haleon (LON:HLN) last issued its quarterly earnings results on Thursday, July 30th. The company reported GBX 8.60 EPS for the quarter. Haleon had a return on equity of 9.89% and a net margin of 14.55%. Research analysts expect that Haleon plc will post 19.50 earnings per share for the current fiscal year.

Haleon announced that its Board of Directors has approved a share buyback program on Thursday, October 29th that allows the company to buy back £500 million in shares. This buyback authorization allows the company to purchase up to 1.8% of its shares through open market purchases. Stock buyback programs are often an indication that the company’s board of directors believes its shares are undervalued.

Haleon Company Profile

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.